Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label pediatric study of weekly BIVV001 in severe hemophilia A
NL-OMON49869Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Feb 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of efanesoctocog alfa in hemophilia A, sponsored by Sanofi. Primary endpoint: Occurrence of inhibitor development. Planned start Feb 2021; status: not yet recruiting.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON49869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49869.